Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?

Detalles Bibliográficos
Autores principales: Tokumaru, Yoshihisa, Le, Lan, Asaoka, Mariko, Futamura, Manabu, Ishikawa, Takashi, Yoshida, Kazuhiro, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580860/
https://www.ncbi.nlm.nih.gov/pubmed/33102162
http://dx.doi.org/10.21037/tcr-20-2231
_version_ 1783598858286137344
author Tokumaru, Yoshihisa
Le, Lan
Asaoka, Mariko
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Takabe, Kazuaki
author_facet Tokumaru, Yoshihisa
Le, Lan
Asaoka, Mariko
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Takabe, Kazuaki
author_sort Tokumaru, Yoshihisa
collection PubMed
description
format Online
Article
Text
id pubmed-7580860
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-75808602020-10-22 Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients? Tokumaru, Yoshihisa Le, Lan Asaoka, Mariko Futamura, Manabu Ishikawa, Takashi Yoshida, Kazuhiro Takabe, Kazuaki Transl Cancer Res Editorial Commentary AME Publishing Company 2020-07 /pmc/articles/PMC7580860/ /pubmed/33102162 http://dx.doi.org/10.21037/tcr-20-2231 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Tokumaru, Yoshihisa
Le, Lan
Asaoka, Mariko
Futamura, Manabu
Ishikawa, Takashi
Yoshida, Kazuhiro
Takabe, Kazuaki
Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title_full Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title_fullStr Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title_full_unstemmed Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title_short Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
title_sort should we target “intermediate expression” of her2 in older estrogen receptor positive patients?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580860/
https://www.ncbi.nlm.nih.gov/pubmed/33102162
http://dx.doi.org/10.21037/tcr-20-2231
work_keys_str_mv AT tokumaruyoshihisa shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT lelan shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT asaokamariko shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT futamuramanabu shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT ishikawatakashi shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT yoshidakazuhiro shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients
AT takabekazuaki shouldwetargetintermediateexpressionofher2inolderestrogenreceptorpositivepatients

Ejemplares similares